镇静剂/催眠药
镇静剂
医学
催眠药
巴氯芬
戒断综合征
异丙酚
药品
苯巴比妥
戒毒
药理学
镇静
酒精戒断综合征
苯二氮卓
麻醉
内科学
兴奋剂
酒
受体
生物化学
化学
作者
Cynthia Santos,Ruben Olmedo,Jeremy Kim
出处
期刊:PubMed
日期:2017-03-22
卷期号:19 (3 Suppl Points & Pearls): S1-S2
被引量:6
摘要
Sedative-hypnotic drugs include gamma-Aminobutyric acid (GABA)ergic agents such as benzodiazepines, barbiturates, gamma-Hydroxybutyric acid [GHB], gamma-Butyrolactone [GBL], baclofen, and ethanol. Chronic use of these substances can cause tolerance, and abrupt cessation or a reduction in the quantity of the drug can precipitate a life-threatening withdrawal syndrome. Benzodiazepines, phenobarbital, propofol, and other GABA agonists or analogues can effectively control symptoms of withdrawal from GABAergic agents. Managing withdrawal symptoms requires a patient-specific approach that takes into account the physiologic pathways of the particular drugs used as well as the patient's age and comorbidities. Adjunctive therapies include alpha agonists, beta blockers, anticonvulsants, and antipsychotics. Newer pharmacological therapies offer promise in managing withdrawal symptoms. [Points & Pearls is a digest of Emergency Medicine Practice].
科研通智能强力驱动
Strongly Powered by AbleSci AI